Subcutaneous infusion of kisspeptin-54 stimulates gonadotrophin release in women and the response correlates with basal oestradiol levels

What Was Tested

The paper reports a study of Kisspeptin-10 and Kisspeptin-54, published as a clinical trial.

Kisspeptin stimulates hypothalamic GnRH secretion resulting in gonadotrophin release and has potential as a future therapeutic.

Chronic subcutaneous infusion of kisspeptin via a pump (similar to an insulin pump) may provide an alternative route of administration in the future.

The researchers investigated for the first time in humans, the gonadotrophin response to subcutaneous (SC) infusions of kisspeptin-54 in healthy women.

Who Took Part

The study group was 54 women.

PubMed indexes the participants as teenagers, young adults and adults, women only.

How the Study Was Run

In design terms this was a single-blind and placebo-controlled study.

Only one side, usually the women, was kept unaware of whether Kisspeptin-10 was given.

A placebo (an inactive look-alike) gave the Kisspeptin-10 group a baseline to be compared against.

A prospective, single-blinded placebo-controlled study.

Gonadotrophins and oestradiol were measured every 10 min during the infusions.

What Was Measured

The subject headings attached to it are Estradiol, Follicular Phase, Gonadotropin-Releasing Hormone, Gonadotropins, Infusions, Subcutaneous, Kisspeptins and Luteinizing Hormone.

What This Means in Plain Language

The paper is a single-blind and placebo-controlled study of Kisspeptin-10 and Kisspeptin-54 in 54 women.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2016 (Clinical endocrinology), a journal based in England.

More context: the Kisspeptin-10 compound page and the Kisspeptin-54 compound page, all human trials.